53.JPG)
Global Plant-Based Vaccines Market Size is valued at USD 409.5 Mn in 2024 and is predicted to reach USD 2,161.2 Mn by the year 2034 at an 18.2% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
A vital ingredient in the creation of accessible vaccination derivatives is planted life. Plant-based vaccine production reduces the financial burden of infectious diseases in developing countries because of its large production volume and low cost. Numerous clinical trials focus on developing plant-based oral vaccines for therapeutic indications such as influenza, dengue fever, the flu, and the Ebola virus. By avoiding the use of syringes and needles, these immunizations can be given orally, freeing up medical staff for other tasks and reducing the risk of hospitals acquired infections. Due to rising public awareness of these vaccines' benefits and the global spread of infectious diseases, the market for plant-based vaccines is predicted to experience considerable growth during the projection.
Plant-based vaccines are also less expensive and do not require cold-chain shipping. They are easy to store, and adding more space for production is straightforward. The market for vaccines made from plants is expected to grow. To develop plant-based vaccines for various medical applications, the existing and future market participants for plant-based vaccines are concentrating on rigorous clinical practice assessments.
Furthermore, shortly, it was anticipated that the inadequacies, potential for contamination, and environmental issues would restrain the expansion of the global market for plant-based biologics. Pollen can harm non-transgenic harvests, a part of the conventional agricultural exhibition. Pollen contamination incidents in field crop-based Plant Molecular Farming (PMF) outlets, such as those based on maize or rice, expand biosafety situations. Creating recombinant pharmaceutical combinations is now strictly prohibited by U.S. FDA regulations.
The plant-based vaccines market is segmented by vaccine type, application, source, end-user. By vaccine type market is segmented into viral vaccines, bacterial vaccines, parasite & other vaccines. By application, the market is segmented into influenza, COVID-19, veterinary diseases, other infectious diseases, therapeutic vaccines. By source market is segmented into tobacco (nicotiana benthamiana), cereal crops (maize, rice), other plants (potatoes, lettuce, spirulina), plant cell cultures (carrot, tobacco). By end-user, the market is segmented into veterinary sector, human healthcare, and research institutions.
The viral vaccines segment is the key growth driver in the plant-based vaccines market due to its distinctive technological, safety, and economic benefits. Plant-based systems are particularly adept at manufacturing virus-like particles (VLPs) and viral antigens—non-infectious particles that closely resemble actual viruses and trigger robust immune responses without inducing disease. These platforms facilitate quick genetic modification of plants to express novel viral antigens and are well-suited for addressing new viral threats such as SARS-CoV-2. Plant-derived viral vaccines also present increased safety through the exclusion of human or animal pathogen contamination, greater stability, and efficacy—parameters that are crucial during pandemic preparedness and mass immunization. Their cost-effectiveness and scalability make them even more attractive, particularly for large-scale manufacturing during outbreaks.
The influenza segment of the plant-based vaccines market is witnessing robust growth driven by the rising global prevalence of seasonal influenza, which causes millions of illnesses and significant mortality each year. This chronic public health challenge propels the need for more efficient and accessible vaccines. Plant-based systems provide quick, manufacturable, and economical vaccine production, allowing for timely actions against changing influenza threats. Companies such as Medicago have spearheaded quadrivalent influenza vaccines (QIV) development through plant-based approaches, proving to induce high immune responses against multiple strains. The potential to rapidly develop vaccines to counter seasonal outbreaks and pandemics makes plant-based influenza vaccines an integral part of pandemic preparedness strategies globally.
The North American plant-based vaccines market is expected to register the highest market share in revenue shortly due to the development of new byproducts. The rising prevalence of influenza conditions in the local market and the expansion of several private and public research organizations dedicated to R&D activities for the development of plant-based vaccines, a massive industrial base, a strong consumer base with high purchasing power, particularly in developed nations like the U.S. and Canada, are other factors contributing to the expansion. Additionally, the Asia Pacific is anticipated to expand significantly over the forecast period due to the rise in infectious disease cases brought on by the climate of the region and the growing popularity of plant-based vaccines over conventional vaccines among the general public.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 409.5 Mn |
|
Revenue Forecast In 2034 |
USD 2161.2 Mn |
|
Growth Rate CAGR |
CAGR of 18.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Vaccine type, application, source, end-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Creative Biolabs, Medicago Inc., iBio, ICON, EEA Consulting Engineers, Kentucky BioProcessing, Inc., Baiya Phytopharm and Protalix Biotherapeutics. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Plant-Based Vaccines Market Snapshot
Chapter 4. Global Plant-Based Vaccines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Plant-Based Vaccines Market Industry Trends
4.10. Global Plant-Based Vaccines Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Plant-Based Vaccines Market Segmentation 1: By Vaccine Type, Estimates & Trend Analysis
5.1. Market Share by Vaccine Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vaccine Type:
5.2.1. Viral Vaccines
5.2.2. Bacterial Vaccines
5.2.3. Parasite & Other Vaccines
Chapter 6. Plant-Based Vaccines Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the
following Application:
6.2.1. Influenza
6.2.2. COVID-19
6.2.3. Veterinary Diseases
6.2.4. Other Infectious Diseases
6.2.5. Therapeutic Vaccines
Chapter 7. Plant-Based Vaccines Market Segmentation 3: By Source, Estimates & Trend Analysis
7.1. Market Share by Source, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source:
7.2.1. Tobacco (Nicotiana benthamiana)
7.2.2. Cereal Crops (Maize, Rice)
7.2.3. Other Plants (Potatoes, Lettuce, Spirulina)
7.2.4. Plant Cell Cultures (Carrot, Tobacco)
Chapter 8. Plant-Based Vaccines Market Segmentation 3: By End-User, Estimates & Trend Analysis
8.1. Market Share by End-User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
8.2.1. Veterinary Sector
8.2.2. Human Healthcare
8.2.3. Research Institutions
Chapter 9. Plant-Based Vaccines Market Segmentation 4: Regional Estimates & Trend Analysis
9.1. Global Plant-Based Vaccines Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
9.2.3. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.4. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
9.2.5. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.3. Europe
9.3.1. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
9.3.3. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.4. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
9.3.5. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
9.4.3. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.4. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
9.4.5. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.5. Latin America
9.5.1. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
9.5.3. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.4. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
9.5.5. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
9.6.3. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.4. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
9.6.5. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Dow AgroSciences
10.2.1.1. Business Overview
10.2.1.2. Key Vaccine Type/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Aramis Biotechnologies
10.2.3. Protalix Biotherapeutics
10.2.4. iBio Inc. (USA)
10.2.5. Kentucky BioProcessing (USA)
10.2.6. Baiya Phytopharm (Thailand)
10.2.7. Icon Genetics (Germany)
10.2.8. LenioBio (Germany)
10.2.9. Lumen Bioscience (USA)
10.2.10. Leaf Expression Systems (UK)
10.2.11. ZYUS Life Sciences (Canada)
10.2.12. PlantForm Corporation (Canada)
10.2.13. Fraunhofer CMB (USA)
10.2.14. Mazen Animal Health (USA)
Plant-Based Vaccines Market by Vaccine Type -
Plant-Based Vaccines Market by Application -
Plant-Based Vaccines Market by Source -
Plant-Based Vaccines Market by End-User -
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
